Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: seminole who wrote (860)	3/27/1998 1:07:00 PM
From: Russian Bear	Read Replies (1) \| Respond to of 1826

Richard, I am in a pretty good mood today, so I thought I would let my mind wander a bit... To that end, let me ask you to speculate (and I realize that speculation is all it is) about the possible terms of a partnership agreement. Specifically: 1. Do you suppose MGI will licence only European rights, or all non-US (and, presumably, non-Canadian) rights, to 114? 2. Full Phase II and III cost-bearing by the partner? 3. For what sums of money, up-front and in milestones? Assuming what royalty rate? 4. Up-front/milestone payments in cash or in equity purchases, or a combination? Does anyone else have any thoughts on this? Engaging in speculation can be a lot of fun, as long as we are careful to remember that it is just that -- speculation. Regards, RB